Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Companies that pay dividends have been a reliable choice for investors seeking a passive and somewhat stable income.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two ...

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherap ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

MaxCyte (MXCT) announced they are entering into a strategic platform license with TG Therapeutics (TGTX). Under the terms of the agreement, TG ...

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the online marketplace industry, ...